Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Best performing ETF For 2014: First Trust NYSE Arca Biotech ETF (FBT), SPDR S&P Emerging Asia Pacific (ETF) (GMF), IShares Barclays 20+ Yr. Treas.Bond (ETF) (TLT)

Over the years, investing in bonds and stocks has become easier and easier with focus now shifting to exchange-traded funds that continue to gain traction with the investing community. Bloomberg’s Eric Balchunas reports that First Trust NYSE Arca Biotech ETF (NYSEARCA:FBT) came in as the best performing ETF for the year having rallied by 50% followed by the likes of IShares Barclays 20+ Yr. Treas.Bond (ETF) (NYSEARCA:TLT) And DBX ETF Trust (NYSEARCA:DBEF).

10 best industries to invest in

The rally according to Balchunas did come with a lot of skepticism especially on the valuation of the fund.

“They have always been accused of having high valuation. The past five years this thing has gone up 270%. Biotech is an industry that keeps coming every year, usually winners become losers, losers become winners, but this biotech won’t stop,” said Mr. Balchuna.

The biotech space has remained a buzz of activities this year as investors remain confident that big returns are in the pipeline especially on the ongoing development of new drugs as well as medical sciences. First Trust NYSE Arca Biotech ETF (NYSEARCA:FBT) remains arguably the best-performing ETF for the year at the back of its 20 biotech companies. Balchunas notes that one of the stocks in the funds soared by 400% this year.

SPDR S&P Emerging Asia Pacific (ETF) (NYSEARCA:GMF) came out as the best-performing emerging market ETF with its focus on emerging markets of China, India and Taiwan. Its rally was accelerated by China having a good year economically with Taiwan gaining a great deal from its semiconductor business.

Emerging markets continued to perform well especially on the decline of oil prices as most of them are oil importing nations. The ETF rallied by 9% against an average decline of 5% for the entire market, garnering $260 million in the process.

IShares Barclays 20+ Yr. Treas.Bond (ETF) (NYSEARCA:TLT) came out on top as the best-fixed income ETF for the year having soared by 24% having accumulated $3 billion dollars in the process.

“The fact that this did so well because it got a high duration of about 21 years proves that nobody really knows anything about the future. If you had listened to an economist or pundit you would not have been in a ticker like this, and it did exceedingly well taking in more money than it has in its entire life,” said Mr. Balchunas

DBX ETF Trust (NYSEARCA:DBEF), on the other hand, came in as the best international ETF having benefited a great deal from the dollar making substantial gains against other currencies. DBEF was up 4% for the year against the industry average that was down by 5% accumulating $1.2 billion in the process.

Warren Buffett and BillionairesFree Report: Warren Buffett and 12 Billionaires Are Crazy About These 7 Stocks

Let Warren Buffett, David Einhorn, George Soros, and David Tepper WORK FOR YOU. If you want to beat the low cost index funds by an average of 6 percentage points per year look no further than Warren Buffett’s stock picks. That’s the margin Buffett’s stock picks outperformed the market since 2008. In this free report, Insider Monkey’s market beating research team identified 7 stocks Warren Buffett and 12 other billionaires are crazy about. CLICK HERE NOW

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!